Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Chemiluminescent assay

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

CPT® Code 82397 refers to a chemiluminescent assay, which is a specialized laboratory technique used to measure the light emitted from a chemical reaction. This method is a variant of the enzyme-linked immunosorbent assay (ELISA), a widely used immunological test. The chemiluminescent assay is particularly valuable in clinical diagnostics as it allows for the detection and quantification of various substances in biological samples, such as hormones, proteins, and other biomarkers. The light emission that occurs during the chemical reaction is directly proportional to the concentration of the target analyte in the sample, making it a sensitive and specific testing method. The applications of CPT® Code 82397 are diverse, encompassing tests for several important biological markers. For instance, it can be utilized to measure insulin-like growth factor binding protein-3 (IGFBP-3) in patients suspected of having growth disorders. Additionally, it is employed in the assessment of leptin levels, a hormone that plays a crucial role in regulating energy balance and fat storage. The assay is also used to evaluate vascular endothelial growth factor (VEGF), a protein that is essential for angiogenesis, the formation of new blood vessels. Furthermore, the chemiluminescent assay can be applied in the differentiation of thyroid hormone resistance and the diagnosis of thyrotropin-secreting pituitary tumors, as well as in the investigation of delayed puberty disorders through the measurement of alpha subunit levels in pituitary glycoprotein hormones. To perform the chemiluminescent assay, a blood sample is typically collected through venipuncture, which is a separately reportable procedure. The serum or plasma obtained from the blood sample is then subjected to the chemiluminescent immunoassay, allowing for the detection of the specific factors, hormones, or proteins of interest.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The chemiluminescent assay, represented by CPT® Code 82397, is indicated for various clinical scenarios where precise measurement of specific biomarkers is essential for diagnosis and management. The following conditions and factors may warrant the use of this assay:

  • Growth Disorders - The assay is utilized to measure insulin-like growth factor binding protein-3 (IGFBP-3) in patients suspected of having growth disorders, aiding in the evaluation of growth hormone activity.
  • Obesity and Metabolic Disorders - It is employed to assess leptin levels, a hormone that regulates fat storage and energy balance, which is crucial in understanding obesity and metabolic syndromes.
  • Angiogenesis Assessment - The measurement of vascular endothelial growth factor (VEGF) is performed to evaluate conditions related to abnormal blood vessel growth, which can be significant in various diseases, including cancer.
  • Thyroid Disorders - The assay helps differentiate between thyroid hormone resistance and thyrotropin-secreting pituitary tumors by measuring specific pituitary glycoprotein hormones, which is vital for accurate diagnosis and treatment planning.
  • Delayed Puberty Disorders - It is also indicated in the investigation of delayed puberty disorders through the assessment of alpha subunit levels in pituitary glycoprotein hormones.

2. Procedure

The procedure for conducting a chemiluminescent assay involves several key steps that ensure accurate measurement of the target analytes. The following procedural steps outline the process:

  • Step 1: Sample Collection - A blood sample is obtained from the patient through venipuncture, which is a standard procedure for collecting blood. This step is crucial as it provides the serum or plasma needed for the assay.
  • Step 2: Sample Preparation - Once the blood sample is collected, it is processed to separate the serum or plasma from the cellular components. This preparation is essential to ensure that the assay measures only the relevant biomarkers without interference from blood cells.
  • Step 3: Assay Execution - The prepared serum or plasma is then subjected to the chemiluminescent immunoassay. This involves adding specific reagents that will react with the target analytes, resulting in a chemical reaction that emits light.
  • Step 4: Measurement - The emitted light is measured using a specialized detector. The intensity of the light is directly proportional to the concentration of the target analyte in the sample, allowing for quantification.
  • Step 5: Result Interpretation - The results of the assay are interpreted by healthcare professionals, who will analyze the levels of the measured biomarkers in the context of the patient's clinical condition.

3. Post-Procedure

After the chemiluminescent assay is completed, there are several considerations for post-procedure care and follow-up. Patients may experience minimal discomfort at the venipuncture site, which typically resolves quickly. It is important for healthcare providers to monitor the patient for any adverse reactions, although these are rare. The results of the assay will be compiled and analyzed, and healthcare professionals will discuss the findings with the patient, providing necessary guidance based on the results. Follow-up appointments may be scheduled to further evaluate the patient's condition or to discuss additional testing if required. Proper documentation of the procedure and results is essential for maintaining accurate medical records and ensuring continuity of care.

Short Descr CHEMILUMINESCENT ASSAY
Medium Descr CHEMILUMINESCENT ASSAY
Long Descr Chemiluminescent assay
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 4
CCS Clinical Classification 233 - Laboratory - Chemistry and Hematology
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
Q4 Service for ordering/referring physician qualifies as a service exemption
GW Service not related to the hospice patient's terminal condition
76 Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GA Waiver of liability statement issued as required by payer policy, individual case
GZ Item or service expected to be denied as not reasonable and necessary
Date
Action
Notes
1993-01-01 Added First appearance in code book in 1993.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"